The Centre for Dermatology

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Psoriasis7 trials
• Atopic dermatitis (eczema)4 trials
• Vitiligo1 trial

Phase

• Phase 310 trials
• Phase 22 trials

Status

• Completed6 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Alumis Inc2 trials
• Amgen2 trials
• Bristol-Myers Squibb2 trials
• Eli Lilly and Company2 trials
• Takeda2 trials
• and 2 more

Running trials

• Not yet recruiting

  A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis

  NCT07914231· Phase 2· Coultreon Biopharma· Source

  Contact: Helen Timmis

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

  Contact: Mani Raman (principal investigator)

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· Phase 3· Bristol-Myers Squibb· Source

  Contact: Mani Raman, Site 0144

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

  Contact: Mani Raman, Site 0488

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis3 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source